Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients

Summary

This is an exploratory, Phase 2, multicenter, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, and efficacy of oral treatment with VYNT-0126 in female subjects 18-45 years of age with Rett syndrome.

Timeline

Start

2023-03

Primary completion

2024-03

Completion

2024-06

Drugs

Indications